TNFR2 inhibitor (unnamed)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TNFR2 inhibitor (unnamed), covering 2025-07-08 to 2025-07-08. Get the full timeline:
Most recent: Clinical Trial Update: A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System [Phase 1]